Cardiovascular disease is the leading cause of mortality worldwide. Accounting for 36% of deaths resulting from cardiovascular disease, heart failure affects over 5.7 million Americans1 and 23 million people globally.2 In the United States, an estimated 915,000 people are newly diagnosed with heart failure annually, and over 8 million people are projected to have heart failure by 2030.1,3 Although there has been improvement in survival after diagnosis, the 5-year mortality rate remains at approximately 50%.1,4,5 Although heart transplantation is the ideal treatment for patients with advanced heart failure, the number of transplant candidates unfortunately continues to exceed the number of suitable donors. Over the past decade, the adult transplant waiting list has increased by 34%, whereas the number of donors has remained the same.6 Because of this high demand and lack of supply, mechanical circulatory support has become more prevalent.
Indications for Total Artificial Heart Implantation
Mechanical circulatory support devices are used in patients with worsening advanced heart failure despite optimal pharmacologic therapy. A ventricular assist device is indicated for use as a bridge to transplantation, destination therapy, or a bridge to myocardial recovery. Most devices are implanted for left ventricular failure, but for some patients, right ventricular support may also be necessary, even if right ventricular function appears normal preoperatively. Right ventricular failure has previously been reported to occur on average between 10% and 40% of patients after left ventricular assist device (LVAD) placement and has been associated with higher morbidity and mortality, including a decreased rate of survival to transplantation.7–19 Several studies have identified varying risk factors for developing right ventricular failure after LVAD placement based on patient characteristics, hemodynamic factors, laboratory data, and echocardiographic imaging.7–23 There is no single consistent risk factor, but some recurring variables include elevated serum creatinine,16,18,23 elevated serum bilirubin,8,16 elevated serum hepatic function enzymes,16,18 decreased right ventricular stroke work index,8,12,17,19,23 elevated central venous pressure,8,9,14 preoperative use of an intra-aortic balloon pump,10,13 and severe tricuspid regurgitation.14,22 Patients being evaluated for mechanical circulatory support who appear to be at high risk of worsening right ventricular function after isolated LVAD insertion should be considered for planned biventricular support, because outcomes appear superior with primary biventricular device placement versus late conversion.24
The total artificial heart (TAH) offers biventricular support for patients with severe biventricular failure as a bridge to orthotopic cardiac transplantation. In the past 10 years, over 75% of patients receiving a TAH were categorized as Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS®) profiles 1 or 2,a corresponding with critical cardiogenic shock and progressive decline on inotropes, respectively (Table 1).25 These patients are at high risk for imminent death. Recent data from INTERMACS® suggest that survival outcomes are slightly better for patients implanted with a TAH compared with patients receiving other biventricular assist devices.26 Survival rates at 3 and 6 months after TAH implantation were 76% and 65%, respectively, and 45% of TAH patients in the last 10 years were transplanted by 6 months.a Applications for the TAH include use in patients with significant coexisting cardiac pathologies such as severe refractory arrhythmias, structural defects such as ischemic ventricular septal defect or ventricular wall rupture, intracardiac mass such as thrombus or aneurysm, infiltrative diseases such as amyloidosis or tumors, failed prior cardiac transplant, ventricular failure with presence of a mechanical valve prosthesis, and right ventricular failure in the presence of an LVAD.27–29
Brief History of the Total Artificial Heart
Research and development of the TAH started blossoming in the late 1950s and 1960s. Early leaders in the field included Dr Willem Kolff, Dr Tetsuzo Akutsu, Dr Michael DeBakey, and Dr Domingo Liotta. In 1957, Akutsu and Kolff at the Cleveland Clinic performed a TAH implant into a dog that survived for 90 minutes.30,31 Liotta at the National University of Córdoba, Argentina, started developing a TAH in 1958, which resulted in his recruitment to DeBakey’s team at Baylor College of Medicine in Texas in 1961. In a mission spearheaded by DeBakey in 1964, former U.S. President Lyndon B. Johnson approved financial support for the U.S. Artificial Heart Program with a goal of creating a TAH within 10 years.28,32
Dr Denton Cooley at the Texas Heart Institute performed the first TAH human implant in 1969 using a TAH designed by Liotta. Haskell Karp, a 47-year-old man with advanced heart failure, severe coronary artery disease, and postinfarction ventricular aneurysm, underwent ventricular remodeling surgery and aneurysm resection. He was implanted with the Liotta TAH when he failed weaning from cardiopulmonary bypass. He was extubated on the first postoperative day and was sustained on the TAH for 64 hours until he received a heart transplant. Unfortunately, he died 32 hours posttransplantation secondary to pneumonia and renal failure.33,34
Akutsu joined the team at the Texas Heart Institute in 1974, leading to the development of the Akutsu III TAH.35 This led to the second human TAH implantation in 1981 in a 36-year-old man with refractory ventricular fibrillation after coronary artery bypass surgery. The Akutsu III TAH supported him for 55 hours until he received a donor heart. He died approximately a week later secondary to multiorgan failure and sepsis.36 In the meantime, Akutsu’s former colleague, Kolff, had moved from the Cleveland Clinic to the University of Utah, where he and Dr Robert Jarvik developed the Jarvik-7 TAH. In 1982 at the University of Utah, Dr William DeVries implanted the first Jarvik-7 TAH in the third human TAH recipient, a 61-year-old retired dentist named Barney Clark. He was ineligible for a heart transplant and was supported by the Jarvik-7 for 112 days.37,38 By 1991, the Jarvik-7 TAH had been implanted in 198 patients.28 Secondary to changes in ownership, the Jarvik-7 TAH has been renamed multiple times to the Symbion Artificial Heart, the CardioWest™ TAH, and, since 2001, the SynCardia temporary TAH (TAH-t; SynCardia Systems, Inc, Tucson, AZ). The U.S. Food and Drug Administration (FDA) approved this device in 2004 for use as a bridge to transplant and granted approval in 2014 for an investigational study for use as destination therapy. The SynCardia TAH-t remains the only device to have full approval by the FDA, Health Canada, and European Union as a bridge to transplant. The only other TAH with FDA approval is the AbioCor® Implantable Replacement Heart (IRH; Abiomed, Inc, Danvers, MA), which received approval in 2006 as a Humanitarian Use Device. The CARMAT® TAH (CARMAT SA, Vélizy-Villacoublay, France) that has been developed in France has been implanted in 4 patients to date, completing a feasibility study, which was approved in 2013.39,40
SynCardia Temporary Total Artificial Heart
The SynCardia TAH-t is a pulsatile, pneumatically driven pump that is implanted orthotopically, replacing both native ventricles and all 4 valves (Figure 1). The 2 artificial ventricles are made with polyurethane, and each ventricle contains a 4-layer diaphragm that separates the air chambers from the blood chambers. SynCardia SynHall™ (SynCardia Systems, Inc, Tucson, AZ) mechanical valves, 27 mm inflow and 25 mm outflow, direct blood flow in each ventricle. Two tunneled drivelines deliver compressed air to the diaphragms in each ventricle. Maximum stroke volume is 70 mL, resulting in a cardiac output of 7 to 9 L/min. The drivelines are connected to an external console that provides diagnostic information and controls device settings.28,41–43 Device beat rate, duration of systole, and driving pressures may be manually configured, typically with ranges such as: (1) beat rate between 100 and 130 beats per minute; (2) systolic duration 50% to 60%; (3) right ventricular driving pressure 30 mm Hg above pulmonary artery pressure at approximately 50 to 70 mm Hg; and (4) left ventricular driving pressure 60 mm Hg above systemic pressure at approximately 180 to 200 mm Hg. Filling volumes of 50 to 60 mL per beat are ideal in the 70 mL TAH-t, allowing for a 10- to 20-mL safety window to accommodate episodes of increased venous return.41 A diastolic vacuum, usually set at approximately 10 mm Hg, may be applied to augment filling, but only when the chest is closed to avoid air entrainment.43 Normal pressure and flow waveforms should reflect the “partial fill/full eject” design of the TAH-t (Figures 2 and 3).
An important consideration is the size limitation of the SynCardia TAH-t, which displaces 400 mL of space. To minimize complications associated with improper fit, the TAH-t is generally restricted to patients with a body surface area of greater than 1.7 m2 or with an intrathoracic anteroposterior diameter of greater than 10 cm at the level of the tenth thoracic vertebra based on computed tomographic imaging.42 A smaller 50-mL version has been designed to address smaller adults and pediatric patients (Figure 4). Earlier in 2015, the FDA approved a clinical trial studying the 50 mL as a bridge to transplant.
AbioCor® Implantable Replacement Heart
The AbioCor® IRH developed by Abiomed and the Texas Heart Institute is a fully implantable device, omitting percutaneous external drivelines and maintaining skin barrier integrity. It uses electrohydraulic energy via a transcutaneous energy transmission system to produce pulsatile blood flow. All inner surfaces and all 4 valves of the IRH are made with a polyurethane plastic material (Angioflex®; Abiomed, Inc, Danvers, MA) resistant to calcification.44 The IRH weighs 1090 g and displaces 800 mL of space.45 It is able to produce a stroke volume of approximately 60 mL and generate a cardiac output of 4 to 8 L/min.46
Between 2001 and 2004, the AbioCor® IRH was implanted in 14 patients as destination therapy.28,44,47 Cerebrovascular accidents and device thrombi were common complications noted among the patients.47,48 In 2006, the FDA granted the AbioCor® IRH Humanitarian Device Exemption status for use in patients with severe biventricular failure who are not eligible for heart transplantation. Since approval, it has only been implanted once in 2009.
CARMAT® Total Artificial Heart
The CARMAT® TAH created in France by Dr Alain Carpentier and his team is a pulsatile, electrohydraulically driven device that displaces approximately 750 mL of space. Pressure sensors embedded within the ventricles continuously measure preload and afterload. Internal electronics and microprocessors utilize a control algorithm to produce stroke volumes of 30 to 65 mL and flows of 2 to 9 L/min based on pressures. All blood-contacting surfaces and valves are made of bioprosthetic materials, and a single 8-mm percutaneous driveline provides power.39,40 The first 2 patients implanted with the C-TAH were supported for 74 and 270 days until they died from device failure and multiorgan failure, respectively. There were no thromboembolic complications, and no thrombus formation was noted on autopsy.40
Preoperative and Intraoperative Management of Total Artificial Heart Implantation
Management of TAH recipients during the preoperative and intraoperative periods has been previously discussed in detail27,43 and thus is only mentioned here in brief. Potential TAH recipients are all critically ill patients likely with multiorgan failure from decreased cardiac output and perfusion. These patients are typically already receiving some form of hemodynamic support, which may include inotropic agents or ventricular assist devices. Any inotropic or device support should be continued during the intraoperative period until the patient is placed on cardiopulmonary bypass.
Like most other major cardiac surgeries, intraoperative monitors and lines should include standard American Society of Anesthesiologists monitors, at least 1 arterial catheter, at least 1 central venous catheter, and transesophageal echocardiography. Many patients may already have indwelling central venous and arterial catheters, which may be used if there are no concerns for infection. If there is a pulmonary artery catheter present, it must be removed before cardiopulmonary bypass to avoid being in the surgical field. Induction of general anesthesia should take into account severe biventricular failure with likely multiorgan dysfunction.
Transesophageal echocardiography is performed before and after cardiopulmonary bypass (Figure 5) with emphasis on looking for TAH compression of the venae cavae (inferior more than superior) and pulmonary veins (left more than right). Compression of these vessels occurs especially when the chest is closed or whether the TAH is implanted in a smaller thoracic cavity.49,50 Echocardiographic findings indicative of caval compression include narrowing near the cavoatrial junction, turbulent flow distal to the narrowing or into the right atrium, flow acceleration across the stenosis, and decrease in right atrial size (Figure 6).49–52 Abnormal echocardiographic findings that may identify pulmonary vein obstruction include a turbulent flow pattern with loss of triphasic or quadriphasic pattern and high-flow systolic or diastolic velocities greater than 1.1 m/s (normal 0.4–0.7 m/s).50,53
There is a high likelihood of intraoperative blood product transfusion. Major risk factors for bleeding include preoperative anticoagulation, hepatic dysfunction, renal failure, and redo sternotomy. Postoperative mediastinal bleeding requiring surgical re-exploration is reported in 20% to 39% of TAH patients.42,45,54,55 Bleeding resulting in repeat surgery mostly occurs within the first postoperative month with the highest incidence reported during the first week.42,45,54 Delayed bleeding after the first postoperative month is rare but has been reported.56 If intraoperative hemostasis is inadequate, the chest may be left open for delayed sternal closure to decrease risk of tamponade. This technique has been shown to be beneficial in major cardiac surgery,57 including implant surgery for ventricular assist devices58 and TAH.59 There does not appear to be an increased risk for infection associated with delayed sternal closure in the device population.58,59
Postoperative Management in the Intensive Care Unit
Hemodynamic Monitoring and Considerations.
Monitoring for the postoperative TAH patient includes pulse oximetry, arterial blood pressure monitoring, central venous pressure monitoring, and temperature. Electrocardiography is not necessary because the patient will no longer have electrical activity. Typically the arterial pressure is measured invasively via a radial arterial catheter or, less frequently, a femoral arterial catheter. Because the TAH is a pulsatile device, there should be an arterial waveform. The patient will also have central venous access usually by means of a central line in the right or left internal jugular vein. It is crucial to confirm appropriate positioning of the central line to prevent TAH inflow valve interference and device malfunction.42,60,61 The central line should not enter the right atrium, because the catheter may become trapped in the tricuspid valve and cause pump arrest leading to death.42,54,60 If the patient requires replacement of central access (including peripherally inserted central catheters), ideally the line should not go beyond the junction of the innominate vein and the superior vena cava, and placement is best done with fluoroscopic guidance to prevent the catastrophic complication of wire or line interference with the TAH. A chest radiograph obtained on intensive care unit (ICU) admission may be used to confirm optimal central line and endotracheal tube positioning.
The TAH is sensitive to preload, and thus maintenance of venous tone and intravascular volume is important. TAH patients generally will be hypertensive secondary to vasomotor dysregulation and will require vasodilators such as nicardipine, nitroprusside, or nitroglycerin. The nitrovasodilators have rapid onsets of action and short half-lives, allowing for easy titration; however, both have a risk of tachyphylaxis and increased shunt from inhibition of hypoxic pulmonary vasoconstriction. Nitroprusside also has the risk of cyanide toxicity with prolonged treatment, especially in patients with renal failure. Nitroglycerin produces greater venodilation and may cause too much of a decrease in preload, which the TAH cannot tolerate. Nicardipine, a dihydropyridine calcium channel blocker, is a good alternative to the nitrovasodilators, but it cannot be as rapidly titrated secondary to its slower onset time and longer elimination half-life. If there is vasoplegia after weaning from cardiopulmonary bypass, vasopressors such as vasopressin62–66 or low-dose norepinephrine67–70 are preferred, because these tend to have less effect than other vasoconstrictors such as phenylephrine or epinephrine on pulmonary vascular pressures. Inotropic and chronotropic support will be ineffective given the lack of myocardium, although TAH settings can be adjusted to improve cardiac output and oxygen delivery.
Overall volume status of the patient with a TAH can be deceptive because the device settings can be manipulated to provide a normal cardiac output even in the setting of hypovolemia. Signs of hypovolemia include decreased mean arterial pressure, low fill volumes, and decreased central venous pressure. If prolonged, hypovolemia and decreased fill volumes may lead to poor organ perfusion and result in altered mental status, delayed capillary refill, clammy or diaphoretic skin, and decreased urine output. Laboratory findings of decreased organ perfusion may include an elevated serum lactate, elevated base deficit, and metabolic acidosis. On the other hand, acute volume overload may result in hypertension, elevated central venous pressure, and pulmonary edema.
A sudden drop in flow, fill volume, or cardiac output may indicate driveline or inflow obstruction. Inspection of the drivelines may reveal a mechanical obstruction such as a kink. Serious device malfunctions are rare, but there have been a few cases of diaphragm ruptures and driveline tears.42,61,71,72 Inflow obstruction may be caused by atrial tamponade or venae cavae compression, resulting in a potentially fatal drop in ventricular preload. Atrial tamponade causes a decrease in fill volumes, a decrease in cardiac output, and an increase in central venous pressure. The mediastinal silhouette on chest radiograph may have an altered contour or bulge, which may indicate fluid accumulation.73 As previously mentioned, the pulmonary veins are also susceptible to compression, which may lead to hemodynamic collapse. Pulmonary vein obstruction is often first noted by an increase in pulmonary venous congestion with a concomitant increase in oxygen requirement and opacification of the chest radiograph. If left unidentified or untreated, any venous inflow obstruction may lead to cardiac arrest. Transesophageal echocardiography should be used to exclude compression of the venae cavae or pulmonary veins as well as evaluate for atrial tamponade. Treatment involves immediate surgical re-exploration and evacuation of the pericardial effusion. Standard Advanced Cardiovascular Life Support interventions and chest compressions will not help, because the plastic ventricles are incompressible. Furthermore, vasoconstrictor medications such as epinephrine may actually be dangerous because they may worsen the decreased return to the right ventricle.
Mechanical Ventilatory Support
All postoperative TAH patients will be transported to the ICU intubated and sedated. In some high-volume centers, patients are routinely left with an open chest given the high risk of postoperative bleeding. The oscillations from the TAH may cause autocycling, or inappropriate ventilator triggering, if a flow trigger setting is used. Autocycling may be resolved by using a pressure trigger setting.74 Like with other cardiac surgical patients, the goal is early extubation to prevent ventilator-associated complications such as atelectasis and pneumonia. Patients are extubated once the chest is closed and hemodynamic parameters are stable. For patients requiring a longer period of ventilatory support, standard measures such as head of bed elevation, daily sedation vacations, and chlorhexidine oral care should be utilized to improve outcomes.75
Patients with advanced heart failure have increased levels of brain natriuretic peptide secondary to chronic ventricular myocyte stretching. Brain natriuretic peptide is a potent vasodilatory hormone produced primarily by the ventricles that aids in volume homeostasis and blood pressure regulation.76–78 With worsening heart failure, there is a decrease in renal responsiveness to this hormone. Some proposed explanations include downregulation of natriuretic peptide renal receptors, decreased natriuretic peptide availability, and altered signaling.79 A patient with a newly implanted TAH no longer has the main endogenous source of brain natriuretic peptide and may develop acute kidney injury even if renal function was normal preoperatively.61 INTERMACS® data from the past decade reveal that approximately one-third of TAH patients experienced renal dysfunction.a An infusion of nesiritide, a recombinant form of human brain natriuretic peptide, may be beneficial to maintain urine output and renal function until levels normalize.80–82 At the authors’ institution, patients who do require nesiritide generally need a very slow wean.
Patients with any mechanical circulatory support device are at risk for thrombosis and adverse sequelae such as embolic stroke caused by platelet interactions with the device. Pump thrombosis is a major fatal complication that has an average incidence of 2% to 11% in patients with HeartMate II® (Thoratec Corporation, Pleasanton, CA) LVADs.83–87 Device thrombosis around the atrial struts in the AbioCor® IRH was a major complication resulting in stroke and device modification.47,48 However, there have been rare reports of nonfatal thrombi forming within the TAH-t, including 1 mitral valve thrombus88 and 1 thrombus caused by a diaphragm rupture.61 Both patients survived and eventually received heart transplants. Incidence rates of stroke are low and comparable in TAH-t patients and HeartMate II® patients at on average approximately 0.06 to 0.08 events per patient-year.45,54,89–94 In 1 study comparing biventricular assist devices, stroke rates were significantly lower in the TAH-t group at 16% versus 61% in the implantable biventricular assist device group and 57% in the paracorporeal biventricular assist device group.95 Neurologic dysfunction was reported in 25% of TAH patients in recent INTERMACS® data.a
A multitargeted antithrombotic approach that includes both anticoagulation and antiplatelet therapies has been recommended.94,96 Regimens may vary based on institution, but most commonly anticoagulation is achieved with unfractionated heparin with an eventual transition to warfarin, and antiplatelet therapy consists of either aspirin or dipyridamole.94,96,97 When the chest is closed and chest tube output is less than 30 mL/h for 4 hours, then anticoagulation with IV heparin may be started at 2 to 5 units/kg/h.43,45,94 Therapeutic goals may include heparin levels between 0.11 and 0.27 units/mL or an activated partial thromboplastin time of 40 to 60 seconds. Thrombelastograph® or TEG® (Haemonetics Corp, Braintree, MA) can be useful in identifying which parts of the coagulation cascade require therapeutic manipulation. Within the next 1 to 2 weeks, transition to warfarin may be initiated once renal and hepatic functions have recovered.45 Starting doses may range from 2 to 7.5 mg/day.43,45,96 Therapeutic international normalized ratio goals are between 2.0 and 3.0. Both heparin and warfarin dosing should be titrated to normocoagulability based on whole blood TEG® to ensure adequate bridging.45
A potential risk of heparin use is heparin-induced thrombocytopenia, an immune-mediated reaction caused by antibodies formed against heparin–platelet factor 4 complexes. The immune complexes subsequently bind and activate platelets, causing a prothrombotic state. Up to 50% of cardiac surgical patients may have antibodies present, but only 1% to 3% will develop heparin-induced thrombocytopenia.98,99 In patients with ventricular assist devices including the TAH, the incidence has been reported to be approximately 8% to 10%.98–101 Higher levels of antibodies have been associated with higher rates of thrombotic events including stroke.98–101 If the patient develops heparin-induced thrombocytopenia, direct thrombin inhibitors such as bivalirudin and argatroban are a reasonable alternative. The starting dosage of bivalirudin is 0.005 mg/kg/h and is adjusted to normocoagulability based on TEG®, typically falling between the range of 0.01 and 0.02 mg/kg/h.102 Argatroban has been successfully used in patients with ventricular assist devices103,104 with starting doses of 0.02 to 0.42 µg/kg/min and up to 1.5-µg/kg/min maintenance doses.104 Plasmapheresis to reduce antibody load may also be considered, but currently data remain limited.
Antiplatelet therapy with aspirin and/or dipyridamole is promptly started postoperatively as long as platelet count is over 100,000 × 106/L and there are no bleeding complications. Aspirin, usually at 81 mg/day and titrated up to 325 mg/day, may be started when chest tube output is less than 30 mL/h for 4 hours. The aspirin dose may be increased as long as TEG® platelet mapping indicates a maximum amplitude greater than 50 mm. Dipyridamole, at 50 mg every 8 hours and up to 400 mg every 6 hours, may be started immediately on arrival to the ICU. Some protocols additionally recommend the use of pentoxifylline at 200 mg to 400 mg every 8 or 12 hours to help decrease blood viscosity, especially if there is a high amount of hemolysis. It may also be started immediately postimplantation.94,96,97
Postoperative anemia is common in TAH patients and is multifactorial in nature. Bleeding, reported in 47% of all TAH patients in the last 10 years,a is a common adverse event that is likely the main cause of acute anemia. As previously mentioned, mediastinal bleeding usually occurs during the first few postoperative days and may require surgical re-exploration. Gastrointestinal bleeding is another concern, especially when anticoagulation and antiplatelet therapies are initiated. Hemolysis occurs in mechanical devices as a result of wall shear stress and flow acceleration105 and contributes to both acute and chronic anemia. The majority of TAH patients will have laboratory evidence of hemolysis, including decreased haptoglobin, increased plasma-free hemoglobin, increased lactate dehydrogenase, and elevated reticulocyte counts.106 TAH patients also exhibit abnormal hematopoiesis secondary to increased inflammatory markers impairing normal bone marrow response to anemia.106 However, because TAH patients are being bridged to transplant, it is recommended to avoid transfusing blood products as much as possible to avoid foreign antigen exposure. TAH patients may be able to tolerate anemia even as low as a hemoglobin level of 6 g/dL, the transfusion threshold used at the authors’ institution. Chronic anemia associated with the TAH appears to resolve after TAH removal and heart transplantation.106
Patients are routinely started on broad-spectrum antibiotic prophylaxis during the perioperative period. Infections are common in the TAH population with reported rates of up to 53% to 83%.42,54,71,88 The respiratory tract, urinary tract, and drivelines are the most frequent sites of infection.54,72,88,107 Mediastinitis has been reported in 3% to 14% of TAH patients, but rarely has been secondary to ascending driveline infection.45,55,61,71,88 Although rates of infection are high, mortality secondary to infectious causes is on average less than 20%.45,55,72,88
Medications used should cover both Gram-positive and Gram-negative organisms. A common regimen is vancomycin and piperacillin–tazobactam or levofloxacin. There should be at least 1 dose given within 1 hour before surgical incision. Antibiotics are continued for at least 48 hours postoperatively and may be discontinued if there is no concern for infection. If the chest is not closed, adding an antifungal agent such as fluconazole should be considered, and the duration of microbial coverage should be extended. Early extubation, pulmonary toilet, mobilization, and invasive line removal may reduce infection risk. Discussion with an infectious disease specialist is recommended.
Transition Out of the Intensive Care Unit
When the TAH patient has stabilized and no longer needs to be in the ICU, the patient is transferred to a step-down unit. Certain SynCardia TAH-t patients may be considered for transition to the Freedom® portable driver system (SynCardia Systems, Inc, Tucson, AZ), which was designed to allow TAH-t patients to be discharged home. It has approval from the FDA, Health Canada, and European Union. Weighing approximately 6 kg and packaged in a wearable backpack or bag, the Freedom® portable driver liberates the patient from being tethered to a larger pneumatic console (Figures 7 and 8). The Freedom® portable driver display shows beat rate, left ventricular fill volume, and cardiac output, but only the beat rate may be adjusted.108,109 Preliminary experiences have shown that it is possible to safely discharge a TAH-t patient home with a portable driver, allowing for improved quality of life and potential reduction in medical costs while awaiting heart transplantation.109–111
Despite advancements in the medical management of heart failure, the demand for heart transplantation continues to be a growing burden worldwide. The use of mechanical circulatory support has become more prevalent, and clinician familiarity with devices has become more significant. Several TAHs have been developed over the past 60 years, but currently the SynCardia TAH-t is the only 1 being used. The SynCardia TAH-t has shown that it can be an effective bridge to heart transplantation in patients with biventricular failure. With the Freedom® portable driver, certain TAH-t patients may even be discharged home to wait for a transplant offer as an outpatient. TAH technology will continue to evolve with hope that it may offer a more definitive treatment for patients with heart failure in the near future.
Name: Jill Yaung, MD.
Contribution: This author helped write and edit the manuscript.
Conflicts of Interest: None.
Name: Francisco A. Arabia, MD, MBA.
Contribution: This author helped write and edit the manuscript.
Conflicts of Interest: Francisco Arabia is a consultant for BiVACOR®, HeartWare®, and SynCardia Systems, Inc.
Name: Michael Nurok, MBChB, PhD.
Contribution: This author helped write and edit the manuscript.
Conflicts of Interest: None.
This manuscript was handled by: W. Scott Beattie, PhD, MD, FRCPC.
1. Mozaffarian D, Benjamin EJ, Go AS, et al.; American Heart Association Statistics Committee; Stroke Statistics Subcommittee. Heart disease and stroke statistics—2016 update: a report from the American Heart Association. Circulation. 2016;133:e38–e360.
2. McMurray JJ, Petrie MC, Murdoch DR, Davie AP. Clinical epidemiology of heart failure: public and private health burden. Eur Heart J. 1998;19(suppl P):P9–P16.
3. Heidenreich PA, Albert NM, Allen LA, et al.; American Heart Association Advocacy Coordinating Committee; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; Council on Clinical Cardiology; Council on Epidemiology and Prevention; Stroke Council. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail. 2013;6:606–619.
4. Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002;347:1397–1402.
5. Roger VL, Weston SA, Redfield MM, et al. Trends in heart failure incidence and survival in a community-based population. JAMA. 2004;292:344–350.
6. Colvin-Adams M, Smith JM, Heubner BM, et al. OPTN/SRTR 2013 annual data report: heart. Am J Transplant. 2015;15(suppl 2):1–28.
7. Dandel M, Krabatsch T, Falk V. Left ventricular vs. biventricular mechanical support: Decision making and strategies for avoidance of right heart failure after left ventricular assist device implantation. Int J Cardiol. 2015;198:241–250.
8. Kormos RL, Teuteberg JJ, Pagani FD, et al.; HeartMate II Clinical Investigators. Right ventricular failure in patients with the HeartMate II continuous-flow left ventricular assist device: incidence, risk factors, and effect on outcomes. J Thorac Cardiovasc Surg. 2010;139:1316–1324.
9. Dang NC, Topkara VK, Mercando M, et al. Right heart failure after left ventricular assist device implantation in patients with chronic congestive heart failure. J Heart Lung Transplant. 2006;25:1–6.
10. Drakos SG, Janicki L, Horne BD, et al. Risk factors predictive of right ventricular failure after left ventricular assist device implantation. Am J Cardiol. 2010;105:1030–1035.
11. Lampert BC, Teuteberg JJ. Right ventricular failure after left ventricular assist devices. J Heart Lung Transplant. 2015;34:1123–1130.
12. Ochiai Y, McCarthy PM, Smedira NG, et al. Predictors of severe right ventricular failure after implantable left ventricular assist device insertion: analysis of 245 patients. Circulation. 2002;106:1198–1202.
13. Patel ND, Weiss ES, Schaffer J, et al. Right heart dysfunction after left ventricular assist device implantation: a comparison of the pulsatile HeartMate I and axial-flow HeartMate II devices. Ann Thorac Surg. 2008;86:832–840.
14. Atluri P, Goldstone AB, Fairman AS, et al. Predicting right ventricular failure in the modern, continuous flow left ventricular assist device era. Ann Thorac Surg. 2013;96:857–863.
15. Meineri M, Van Rensburg AE, Vegas A. Right ventricular failure after LVAD implantation: prevention and treatment. Best Pract Res Clin Anaesthesiol. 2012;26:217–229.
16. Matthews JC, Koelling TM, Pagani FD, Aaronson KD. The right ventricular failure risk score a pre-operative tool for assessing the risk of right ventricular failure in left ventricular assist device candidates. J Am Coll Cardiol. 2008;51:2163–2172.
17. Fukamachi K, McCarthy PM, Smedira NG, Vargo RL, Starling RC, Young JB. Preoperative risk factors for right ventricular failure after implantable left ventricular assist device insertion. Ann Thorac Surg. 1999;68:2181–2184.
18. Santambrogio L, Bianchi T, Fuardo M, et al. Right ventricular failure after left ventricular assist device insertion: preoperative risk factors. Interact Cardiovasc Thorac Surg. 2006;5:379–382.
19. Morgan JA, John R, Lee BJ, Oz MC, Naka Y. Is severe right ventricular failure in left ventricular assist device recipients a risk factor for unsuccessful bridging to transplant and post-transplant mortality. Ann Thorac Surg. 2004;77:859–863.
20. Raina A, Seetha Rammohan HR, Gertz ZM, Rame JE, Woo YJ, Kirkpatrick JN. Postoperative right ventricular failure after left ventricular assist device placement is predicted by preoperative echocardiographic structural, hemodynamic, and functional parameters. J Card Fail. 2013;19:16–24.
21. Vivo RP, Cordero-Reyes AM, Qamar U, et al. Increased right-to-left ventricle diameter ratio is a strong predictor of right ventricular failure after left ventricular assist device. J Heart Lung Transplant. 2013;32:792–799.
22. Baumwol J, Macdonald PS, Keogh AM, et al. Right heart failure and ‘failure to thrive’ after left ventricular assist device: clinical predictors and outcomes. J Heart Lung Transplant. 2011;30:888–895.
23. Fitzpatrick JR 3rd, Frederick JR, Hsu VM, et al. Risk score derived from pre-operative data analysis predicts the need for biventricular mechanical circulatory support. J Heart Lung Transplant. 2008;27:1286–1292.
24. Fitzpatrick JR 3rd, Frederick JR, Hiesinger W, et al. Early planned institution of biventricular mechanical circulatory support results in improved outcomes compared with delayed conversion of a left ventricular assist device to a biventricular assist device. J Thorac Cardiovasc Surg. 2009;137:971–977.
25. Stevenson LW, Pagani FD, Young JB, et al. INTERMACS profiles of advanced heart failure: the current picture. J Heart Lung Transplant. 2009;28:535–541.
26. Kirklin JK, Naftel DC, Pagani FD, et al. Seventh INTERMACS annual report: 15,000 patients and counting. J Heart Lung Transplant. 2015;34:1495–1504.
27. Sale SM, Smedira NG. Total artificial heart. Best Pract Res Clin Anaesthesiol. 2012;26:147–165.
28. Gray NA Jr, Selzman CH. Current status of the total artificial heart. Am Heart J. 2006;152:4–10.
29. Arabia FA, Moriguchi JD. Machines versus medication for biventricular heart failure: focus on the total artificial heart. Future Cardiol. 2014;10:593–609.
30. Akutsu T, Kolff WJ. Permanent substitutes for valves and hearts. Trans Am Soc Artif Intern Organs. 1957;4:230.
31. Takatani S. In remembrance of Dr. Tetsuzo Akutsu: a man who started artificial heart research. J Artif Organs. 2008;11:1–3.
32. Debakey ME. The odyssey of the artificial heart. Artif Organs. 2000;24:405–411.
33. Cooley DA. Some thoughts about the historic events that led to the first clinical implantation of a total artificial heart. Tex Heart Inst J. 2013;40:117–119.
34. Cooley DA. Recollections of the early years of heart transplantation and the total artificial heart. Artif Organs. 2011;35:353–357.
35. Cooley DA. The total artificial heart. Nat Med. 2003;9:108–111.
36. Cooley DA, Akutsu T, Norman JC, Serrato MA, Frazier OH. Total artificial heart in two-staged cardiac transplantation. Cardiovasc Dis. 1981;8:305–319.
37. Kolff WJ. Early years of artificial organs at the Cleveland Clinic: Part II: open heart surgery and artificial hearts. ASAIO J. 1998;44:123–128.
38. DeVries WC, Anderson JL, Joyce LD, et al. Clinical use of the total artificial heart. N Engl J Med. 1984;310:273–278.
39. Mohacsi P, Leprince P. The CARMAT total artificial heart. Eur J Cardiothorac Surg. 2014;46:933–934.
40. Carpentier A, Latrémouille C, Cholley B, et al. First clinical use of a bioprosthetic total artificial heart: report of two cases. Lancet. 2015;386:1556–1563.
41. Slepian MJ, Smith RG, Copeland JG. Baughman KL, Baumgartner WA. The SynCardia CardioWest™ total artificial heart. In: Treatment of Advanced Heart Disease. 2006:New York, NY: Taylor and Francis Group; 473–490.
42. Copeland JG, Smith RG, Arabia FA, et al.; CardioWest Total Artificial Heart Investigators. Cardiac replacement with a total artificial heart as a bridge to transplantation. N Engl J Med. 2004;351:859–867.
43. Gaitan BD, Thunberg CA, Stansbury LG, et al. Development, current status, and anesthetic management of the implanted artificial heart. J Cardiothorac Vasc Anesth. 2011;25:1179–1192.
44. Dowling RD, Gray LA Jr, Etoch SW, et al. The AbioCor implantable replacement heart. Ann Thorac Surg. 2003;75:S93–S99.
45. Copeland JG, Smith RG, Arabia FA, et al. Total artificial heart bridge to transplantation: a 9-year experience with 62 patients. J Heart Lung Transplant. 2004;23:823–831.
46. Dowling RD, Etoch SW, Stevens KA, Johnson AC, Gray LA Jr.. Current status of the AbioCor implantable replacement heart. Ann Thorac Surg. 2001;71:S147–S149.
47. Dowling RD, Gray LA Jr, Etoch SW, et al. Initial experience with the AbioCor implantable replacement heart system. J Thorac Cardiovasc Surg. 2004;127:131–141.
48. Frazier OH, Dowling RD, Gray LA Jr, Shah NA, Pool T, Gregoric I. The total artificial heart: where we stand. Cardiology. 2004;101:117–121.
49. Arabia FA, Copeland JG, Pavie A, Smith RG. Implantation technique for the CardioWest total artificial heart. Ann Thorac Surg. 1999;68:698–704.
50. Mizuguchi KA, Padera RF Jr, Kowalczyk A, Doran MN, Couper GS, Fox AA. Transesophageal echocardiography imaging of the total artificial heart. Anesth Analg. 2013;117:780–784.
51. Sharma V, Wasowicz M, Brister S, Karski J, Meineri M. Postoperative transesophageal echocardiography diagnosis of inferior vena cava obstruction after mitral valve replacement. Anesth Analg. 2011;113:1343–1346.
52. Fine NM, Gopalan RS, Arabia FA, Kushwaha SS, Chandrasekaran K. Intraoperative transesophageal echocardiographic guidance of total artificial heart implantation. J Heart Lung Transplant. 2014;33:454–457.
53. Obeid AI, Carlson RJ. Evaluation of pulmonary vein stenosis by transesophageal echocardiography. J Am Soc Echocardiogr. 1995;8:888–896.
54. Copeland JG, Copeland H, Gustafson M, et al. Experience with more than 100 total artificial heart implants. J Thorac Cardiovasc Surg. 2012;143:727–734.
55. Kirsch ME, Nguyen A, Mastroianni C, et al. SynCardia temporary total artificial heart as bridge to transplantation: current results at La Pitié Hospital. Ann Thorac Surg. 2013;95:1640–1646.
56. Hermsen JL, Smith JW, Pal JD, et al. Late surgical bleeding following total artificial heart implantation. J Card Surg. 2015;30:771–774.
57. Christenson JT, Maurice J, Simonet F, Velebit V, Schmuziger M. Open chest and delayed sternal closure after cardiac surgery. Eur J Cardiothorac Surg. 1996;10:305–311.
58. Stulak JM, Romans T, Cowger J, et al. Delayed sternal closure does not increase late infection risk in patients undergoing left ventricular assist device implantation. J Heart Lung Transplant. 2012;31:1115–1119.
59. Spiliopoulos S, Autschbach R, Koerfer R, Tenderich G. Delayed sternal closure after total artificial heart implantation. J Thorac Cardiovasc Surg. 2015;150:417–418.
60. Zimmerman H, Coehlo-Anderson R, Slepian M, Smith RG, Sethi G, Copeland JG. Device malfunction of the CardioWest total artificial heart secondary to catheter entrapment of the tricuspid valve. ASAIO J. 2010;56:481–482.
61. El-Banayosy A, Arusoglu L, Morshuis M, et al. CardioWest total artificial heart: Bad Oeynhausen experience. Ann Thorac Surg. 2005;80:548–552.
62. Tayama E, Ueda T, Shojima T, et al. Arginine vasopressin is an ideal drug after cardiac surgery for the management of low systemic vascular resistant hypotension concomitant with pulmonary hypertension. Interact Cardiovasc Thorac Surg. 2007;6:715–719.
63. Currigan DA, Hughes RJ, Wright CE, Angus JA, Soeding PF. Vasoconstrictor responses to vasopressor agents in human pulmonary and radial arteries: an in vitro study. Anesthesiology. 2014;121:930–936.
64. Evora PR, Pearson PJ, Schaff HV. Arginine vasopressin induces endothelium-dependent vasodilatation of the pulmonary artery. V1-receptor-mediated production of nitric oxide. Chest. 1993;103:1241–1245.
65. Wallace AW, Tunin CM, Shoukas AA. Effects of vasopressin on pulmonary and systemic vascular mechanics. Am J Physiol. 1989;257:H1228–H1234.
66. Holmes CL, Landry DW, Granton JT. Science review: vasopressin and the cardiovascular system part 2—clinical physiology. Crit Care. 2004;8:15–23.
67. Hoeper MM, Granton J. Intensive care unit management of patients with severe pulmonary hypertension and right heart failure. Am J Respir Crit Care Med. 2011;184:1114–1124.
68. Kerbaul F, Rondelet B, Motte S, et al. Effects of norepinephrine and dobutamine on pressure load-induced right ventricular failure. Crit Care Med. 2004;32:1035–1040.
69. Price LC, Wort SJ, Finney SJ, Marino PS, Brett SJ. Pulmonary vascular and right ventricular dysfunction in adult critical care: current and emerging options for management: a systematic literature review. Crit Care. 2010;14:R169.
70. Kwak YL, Lee CS, Park YH, Hong YW. The effect of phenylephrine and norepinephrine in patients with chronic pulmonary hypertension*. Anaesthesia. 2002;57:9–14
71. Torregrossa G, Morshuis M, Varghese R, et al. Results with SynCardia total artificial heart beyond 1 year. ASAIO J. 2014;60:626–634.
72. Leprince P, Bonnet N, Rama A, et al. Bridge to transplantation with the Jarvik-7 (CardioWest) total artificial heart: a single-center 15-year experience. J Heart Lung Transplant. 2003;22:1296–1303.
73. Parker MS, Fahrner LJ, Deuell BP, et al. Total artificial heart implantation: clinical indications, expected postoperative imaging findings, and recognition of complications. AJR Am J Roentgenol. 2014;202:W191–W201.
74. Shoham AB, Patel B, Arabia FA, Murray MJ. Mechanical ventilation and the total artificial heart: optimal ventilator trigger to avoid post-operative autocycling—a case series and literature review. J Cardiothorac Surg. 2010;5:39.
75. Tablan OC, Anderson LJ, Besser R, Bridges C, Hajjeh R; CDC; Healthcare Infection Control Practices Advisory Committee. Guidelines for preventing health-care–associated pneumonia, 2003: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. MMWR Recomm Rep. 2004;53:1–36.
76. Chen HH, Burnett JC. Natriuretic peptides in the pathophysiology of congestive heart failure. Curr Cardiol Rep. 2000;2:198–205.
77. Cho Y, Somer BG, Amatya A. Natriuretic peptides and their therapeutic potential. Heart Dis. 1999;1:305–328.
78. de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet. 2003;362:316–322.
79. Egom EE, Feridooni T, Hotchkiss A, Kruzliak P, Pasumarthi KB. Mechanisms of renal hyporesponsiveness to BNP in heart failure. Can J Physiol Pharmacol. 2015;93:399–403.
80. Delgado R 3rd, Wadia Y, Kar B, et al. Role of B-type natriuretic peptide and effect of nesiritide after total cardiac replacement with the AbioCor total artificial heart. J Heart Lung Transplant. 2005;24:1166–1170.
81. Shah KB, Tang DG, Kasirajan V, Gunnerson KJ, Hess ML, Sica DA. Impact of low-dose B-type natriuretic peptide infusion on urine output after total artificial heart implantation. J Heart Lung Transplant. 2012;31:670–672.
82. Spiliopoulos S, Guersoy D, Koerfer R, Tenderich G. B-type natriuretic peptide therapy in total artificial heart implantation: renal effects with early initiation. J Heart Lung Transplant. 2014;33:662–663.
83. Starling RC, Moazami N, Silvestry SC, et al. Unexpected abrupt increase in left ventricular assist device thrombosis. N Engl J Med. 2014;370:33–40.
84. Kirklin JK, Naftel DC, Kormos RL, et al. Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) analysis of pump thrombosis in the HeartMate II left ventricular assist device. J Heart Lung Transplant. 2014;33:12–22
85. Uriel N, Han J, Morrison KA, et al. Device thrombosis in HeartMate II continuous-flow left ventricular assist devices: a multifactorial phenomenon. J Heart Lung Transplant. 2014;33:51–59.
86. Park SJ, Milano CA, Tatooles AJ, et al.; HeartMate II Clinical Investigators. Outcomes in advanced heart failure patients with left ventricular assist devices for destination therapy. Circ Heart Fail. 2012;5:241–248.
87. Stulak JM, Sharma S, Maltais S. Management of pump thrombosis in patients with left ventricular assist devices. Am J Cardiovasc Drugs. 2015;15:89–94.
88. Roussel JC, Sénage T, Baron O, et al. CardioWest (Jarvik) total artificial heart: a single-center experience with 42 patients. Ann Thorac Surg. 2009;87:124–129.
89. Harvey L, Holley C, Roy SS, et al. Stroke after left ventricular assist device implantation: outcomes in the continuous-flow era. Ann Thorac Surg. 2015;100:535–541.
90. Slaughter MS, Rogers JG, Milano CA, et al.; HeartMate II Investigators. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361:2241–2251.
91. Starling RC, Naka Y, Boyle AJ, et al. Results of the post-U.S. Food and Drug Administration-approval study with a continuous flow left ventricular assist device as a bridge to heart transplantation: a prospective study using the INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support). J Am Coll Cardiol. 2011;57:1890–1898.
92. Boyle AJ, Russell SD, Teuteberg JJ, et al. Low thromboembolism and pump thrombosis with the HeartMate II left ventricular assist device: analysis of outpatient anti-coagulation. J Heart Lung Transplant. 2009;28:881–887.
93. Boyle AJ, Jorde UP, Sun B, et al.; HeartMate II Clinical Investigators. Pre-operative risk factors of bleeding and stroke during left ventricular assist device support: an analysis of more than 900 HeartMate II outpatients. J Am Coll Cardiol. 2014;63:880–888.
94. Copeland J, Copeland H, Nolan P, Gustafson M, Slepian M, Smith R. Results with an anticoagulation protocol in 99 SynCardia total artificial heart recipients. ASAIO J. 2013;59:216–220.
95. Kirsch M, Mazzucotelli JP, Roussel JC, et al.; Groupe de Réflexion sur l’Assistance Mécanique. Survival after biventricular mechanical circulatory support: does the type of device matter? J Heart Lung Transplant. 2012;31:501–508.
96. Ensor CR, Cahoon WD, Crouch MA, et al. Antithrombotic therapy for the CardioWest temporary total artificial heart. Tex Heart Inst J. 2010;37:149–158.
97. Szefner J. Control and treatment of hemostasis in cardiovascular surgery. The experience of La Pitié Hospital with patients on total artificial heart. Int J Artif Organs. 1995;18:633–648.
98. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia and cardiac surgery. Ann Thorac Surg. 2003;76:2121–2131.
99. Koster A, Huebler S, Potapov E, et al. Impact of heparin-induced thrombocytopenia on outcome in patients with ventricular assist device support: single-institution experience in 358 consecutive patients. Ann Thorac Surg. 2007;83:72–76.
100. Schenk S, El-Banayosy A, Prohaska W, et al. Heparin-induced thrombocytopenia in patients receiving mechanical circulatory support. J Thorac Cardiovasc Surg. 2006;131:1373–1381.e4.
101. Warkentin TE, Greinacher A, Koster A. Heparin-induced thrombocytopenia in patients with ventricular assist devices: are new prevention strategies required? Ann Thorac Surg. 2009;87:1633–1640.
102. Crouch MA, Kasirajan V, Cahoon W, Katlaps GJ, Gunnerson KJ. Successful use and dosing of bivalirudin after temporary total artificial heart implantation: a case series. Pharmacotherapy. 2008;28:1413–1420.
103. Samuels LE, Kohout J, Casanova-Ghosh E, et al. Argatroban as a primary or secondary postoperative anticoagulant in patients implanted with ventricular assist devices. Ann Thorac Surg. 2008;85:1651–1655.
104. Pappalardo F, Scandroglio AM, Potapov E, et al. Argatroban anticoagulation for heparin induced thrombocytopenia in patients with ventricular assist devices. Minerva Anestesiol. 2012;78:330–335.
105. Yasuda T, Shimokasa K, Funakubo A, Higami T, Kawamura T, Fukui Y. An investigation of blood flow behavior and hemolysis in artificial organs. ASAIO J. 2000;46:527–531.
106. Mankad AK, Tang DG, Clark WB, et al. Persistent anemia after implantation of the total artificial heart. J Card Fail. 2012;18:433–438.
107. Arabía FA, Copeland JG, Smith RG, et al. Infections with the CardioWest total artificial heart. ASAIO J. 1998;44:M336–M339.
108. Jaroszewski DE, Anderson EM, Pierce CN, Arabia FA. The SynCardia freedom driver: a portable driver for discharge home with the total artificial heart. J Heart Lung Transplant. 2011;30:844–845.
109. Friedline K, Hassinger P. Total artificial heart freedom driver in a patient with end-stage biventricular heart failure. AANA J. 2012;80:105–112.
110. Quader MA, Green AJ, Shah KB, Cooke R, Kasirajan V. Hospital readmissions after discharge to home with the Total Artificial Heart Freedom driver: readmission reasons, clinical outcomes, and health care costs. J Heart Lung Transplant. 2016;35:251–252.
111. Demondion P, Fournel L, Niculescu M, Pavie A, Leprince P. The challenge of home discharge with a total artificial heart: the La Pitie Salpetriere experience. Eur J Cardiothorac Surg. 2013;44:843–848.